Targeting FKBP isoforms with small-molecule ligands

Research output: Contribution to journalArticlepeer-review


The FK506 binding protein (FKBP) family of proteins provide an interesting series of drug targets since different isoforms modulate diverse cellular pathways. There are therapeutic opportunities in the fields of cancer therapy, neurodegenerative conditions and psychiatric disorders. X-ray crystallographic or NMR data are available for eight of fourteen human FKBPs covering ten of the twenty-two different FKBP domains. We have made a detailed sequence and structural comparison of human FKBP domains. These data show that the chemical scaffolds common to the immunosuppressive inhibitors FK506 and rapamycin bind to the most conserved region of the binding site. This observation opens the way to the design of isoform specific inhibitors.
Original languageEnglish
Pages (from-to)365-371
Number of pages7
JournalCurrent Opinion in Pharmacology
Issue number4
Early online date29 Jul 2011
Publication statusPublished - 31 Aug 2011


Dive into the research topics of 'Targeting FKBP isoforms with small-molecule ligands'. Together they form a unique fingerprint.

Cite this